168 related articles for article (PubMed ID: 28812918)
1. Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials.
Liu JW; Chen C; Loh EW; Chu CC; Wang MY; Ouyang HJ; Chang YT; Zhuang WZ; Chou CW; Huang DJ; Lee CH; Yen Y; Tam KW
Curr Med Res Opin; 2018 May; 34(5):795-803. PubMed ID: 28812918
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.
Yu J; Liu Z; Su Y; Peng X; Xie Y
Clin Endocrinol (Oxf); 2024 Apr; 100(4):379-388. PubMed ID: 38351437
[TBL] [Abstract][Full Text] [Related]
3. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
[No Abstract] [Full Text] [Related]
4. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.
Oba T; Chino T; Soma A; Shimizu T; Ono M; Ito T; Kanai T; Maeno K; Ito KI
Endocr J; 2020 Dec; 67(12):1215-1226. PubMed ID: 32814730
[TBL] [Abstract][Full Text] [Related]
6. Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis.
Klein Hesselink EN; Steenvoorden D; Kapiteijn E; Corssmit EP; van der Horst-Schrivers AN; Lefrandt JD; Links TP; Dekkers OM
Eur J Endocrinol; 2015 May; 172(5):R215-25. PubMed ID: 25572389
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tyrosine kinase inhibitors for advanced metastatic thyroid cancer: A systematic review and network meta-analysis of randomized controlled trials.
Zhao M; Li R; Song Z; Miao C; Lu J
Medicine (Baltimore); 2024 Apr; 103(15):e37655. PubMed ID: 38608050
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and treatment-related adverse events of multi-targeted tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Zhang K; Wang W; Zhang T; Liang L
Int J Clin Pharm; 2022 Dec; 44(6):1232-1246. PubMed ID: 35951217
[TBL] [Abstract][Full Text] [Related]
10. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
11. Anti-Tumor Activity and Safety of Multikinase Inhibitors in Advanced and/or Metastatic Thyroid Cancer: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Tsoli M; Alexandraki KI; Spei ME; Kaltsas GA; Daskalakis K
Horm Metab Res; 2020 Jan; 52(1):25-31. PubMed ID: 31665790
[TBL] [Abstract][Full Text] [Related]
12. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Massicotte MH; Brassard M; Claude-Desroches M; Borget I; Bonichon F; Giraudet AL; Do Cao C; Chougnet CN; Leboulleux S; Baudin E; Schlumberger M; de la Fouchardière C
Eur J Endocrinol; 2014 Apr; 170(4):575-82. PubMed ID: 24424318
[TBL] [Abstract][Full Text] [Related]
14. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia.
Grasic Kuhar C; Lozar T; Besic N; Music Marolt M
Adv Ther; 2021 Dec; 38(12):5684-5699. PubMed ID: 34674146
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials.
Su J; Wang M; Fu Y; Yan J; Shen Y; Jiang J; Wang J; Lu J; Zhong Y; Lin X; Lin Z; Lin S
Expert Rev Anticancer Ther; 2022 Sep; 22(9):999-1008. PubMed ID: 35833358
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
19. The role of vascular epithelial growth factor receptor-tyrosine kinase inhibitors in the treatment of advanced breast cancer: a meta-analysis of 12 randomized controlled trials.
Li J; Huang S; Zheng W; Ding H; Zhang Y; Huang S; Zhang Z; Chen B; Liang Z; He G; Xiao X; Li S; Xu T; Chen X
Curr Med Res Opin; 2013 Dec; 29(12):1691-9. PubMed ID: 23981081
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials.
Yimaer W; Abudouyimu A; Tian Y; Magaoweiya S; Bagedati D; Wen H
Onco Targets Ther; 2016; 9():1167-73. PubMed ID: 27022276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]